Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 207 clinical trials
featured
Metastatic Colorectal Cancer with wild-type KRAS tumors.

Metastatic Colorectal Cancer with wild-type KRAS tumors.

  • 204 views
  • 08 Nov, 2020
  • 1 location
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)

patients with PIK3CA mutated metastatic colorectal cancer.

metastasis
PIK3CA
oxaliplatin
cetuximab
measurable disease
  • 2 views
  • 27 Jan, 2021
  • 39 locations
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival. The first-line treatment will be conducted with FOLFIRI plus cetuximab, which resulted in a significantly prolonged overall survival versus bevacizumab in the FIRE-3 study. Following initial progression (PD1) it …

metastasis
adjuvant chemotherapy
cetuximab
fluorouracil
folfox regimen
  • 6 views
  • 21 Jan, 2021
  • 1 location
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of

metastasis
measurable disease
solid tumour
platelet count
aptt
  • 0 views
  • 13 Feb, 2021
  • 42 locations
A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

This is a randomized, open-label, multi-center, phase III study of Napabucasin plus bi-weekly FOLFIRI (Arm 1) vs. Napabucasin (Arm 2) for adult patients with metastatic CRC who have failed standard chemotherapy regimens. For patients who have failed bevacizumab with irinotecan-based chemotherapies (treatment failure is defined as radiologic progression of disease …

  • 27 views
  • 23 Jan, 2021
  • 37 locations
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type Metastatic Colorectal Cancer

effectiveness of CMAB009 in combination with a standard and effective chemotherapy FOLFIRI5-Fluorouracil /Folinic acid plus Irinotecanfor RAS/BRAF wild-type, metastatic colorectal cancer in first-line setting

metastasis
folfiri regimen
leucovorin
irinotecan
measurable disease
  • 3 views
  • 25 Jan, 2021
  • 2 locations
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

together with combination chemotherapy with or without capecitabine followed by bevacizumab maintenance therapy in treating patients with metastatic colorectal cancer that cannot be removed by

tumor cells
leucovorin
adjuvant therapy
calcium
monoclonal antibodies
  • 7 views
  • 07 Nov, 2020
  • 1 location
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 cetuximab. Study treatment continues until disease progression or unacceptable toxicity (ie, not for a fixed number of courses). The primary endpoint of the …

modified folfox6
growth factor
neutrophil count
measurable disease
cetuximab
  • 7 views
  • 22 Jan, 2021
  • 1 location
Efficacy and Safety of Olaparib Olaparib + Bevacizumab Compared to Bevacizumab + 5-Fluorouracil (FU)

colorectal cancer (CRC) who have not progressed following first-line induction of FOLFOX with bevacizumab. Hypothesis 1 - Olaparib + Bevacizumab is superior to 5-FU + Bevacizumab with respect to progression

oxaliplatin
systemic chemotherapy
fluorouracil
folfox regimen
chemotherapy regimen
  • 10 views
  • 04 Mar, 2021
  • 96 locations
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

metastatic colorectal cancer that did not respond to fluorouracil.

irinotecan
fluorouracil
monoclonal antibodies
tumor cells
tumor growth
  • 129 views
  • 07 Nov, 2020
  • 12 locations